It’s now almost nine years since the first CAR-T therapies, Kymriah and Yescarta, were approved by the FDA. These therapies and others have revolutionised the treatment of certain hard-to-treat blood cancers, such as ALL and some B-cell lymphomas. There was rightly huge elation at the time. CAR-Ts were a real breakthrough, offering a lifeline – […]
ARE vaccines coming in from the cold? That’s the question this week after Eli Lilly splashed out almost $4 billion on three vaccine biotechs, two of which are in the early stage of clinical development. All are developing jabs for or related to infectious diseases. Why’s this a big deal? Because everyone knows that […]
– New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism – Deal worth up to $415m including upfront and downstream, plus royalties on top – ATLX-1282 is the first programme out of Alchemab’s entirely novel platform which generates and analyses millions of antibody sequences […]
